Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338595 · ClinicalTrials.gov registry record
Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
A clinical trial of Cystic Fibrosis, sponsored by Augusta University.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03338595 is a study of Cystic Fibrosis that has completed, run by Augusta University. The registered enrollment target is 20 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03338595, a study of Cystic Fibrosis, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This project is an attempt to understand how Orkambi treatment affects exercise capacity and the function of the arteries in CF patients who are homozygous F508del. Our goal is to perform the exercise and vascular measurements every 3 months after a patient starts taking Orkambi.
Conditions Studied
Study Locations (1)
Georgia
- Georgia Prevention Institute - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03338595
The ClinicalTrials.gov registry entry for NCT03338595 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT03338595 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03338595 about?
NCT03338595 is a clinical study titled "Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF". This project is an attempt to understand how Orkambi treatment affects exercise capacity and the function of the arteries in CF patients who are homozygous F508del. Our goal is to perform the exercise and vascular measurements every 3 months after a patient starts taking Orkambi.
What is the current status of trial NCT03338595?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-05. Estimated completion is 2020-10.
What conditions does trial NCT03338595 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
Who is sponsoring clinical trial NCT03338595?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03338595 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.